General Information
DRAVP ID DRAVPe00407
Peptide Name EK1C4
Sequence SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG
Sequence Length 41
UniProt ID No entry found
Source Synthetic construct(derived from EK1)
Activity Information
Target Organism SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43,HCoV-229E
Assay pseudovirus inhibition assay
Activity
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity
Binding Target membrane
Mechanism The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells.
Structure Information
PDB ID None
Predicted Structure Download DRAVPe00407
Linear/Cyclic Linear
N-terminal Modification Free
C-terminal Modification PEG4-Chol
Other Modification None
Stereochemistry L
Physicochemical Information
Formula C208H336N48O71S
Absent amino acids CHPRW
Common amino acids EL
Mass 4677.29
Pl 4.36
Basic residues 5
Acidic residues 10
Hydrophobic residues 13
Net charge -5
Boman Index -6701
Hydrophobicity -44.88
Aliphatic Index 104.63
Half Life
Extinction Coefficient cystines 2980
Absorbance 280nm 74.5
Polar residues 11
Literature Information
Literature 1
Title Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.
Pubmed ID 35087243
Reference Cell Res. 2022 Apr;32(4):404-406.
Author Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.
DOI 10.1038/s41422-022-00617-x
Literature 2
Title Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
Pubmed ID 32231345
Reference Cell Res. 2020 Apr;30(4):343-355.
Author Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.